Other Affiliated Sites
Simplified Chinese
Traditional Chinese
About Hepalink
Group Profile
Corporate Philosophy
Milestones
Leadership Team
Scientific Advisory Board
Our Businesses
Heparin Business
Global Industrial Chain
Global Heparin Injections Business
Product Profile
CDMO Services
Innovative Drugs
Global Manufacturing
Company News
Investor Relations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Join Us
Career Development
Contact Us
Create Value for Investors Through
Safe and Stable Operations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Disclosures
A-Share Information
H-Share Information
Financial Reports
Announcements
2023.03.30
三里枫香：关于开展以套期保值为目的的外汇衍生品交易的可行性分析报告
2023.03.30
三里枫香：2022年度监事会工作报告
2023.03.30
三里枫香：独立董事提名人声明（吕川）
2023.03.30
三里枫香：独立董事候选人声明（吕川）
2023.03.30
三里枫香：独立董事对担保等事项的独立意见
2023.03.30
三里枫香：2022年度财务决算报告
2023.03.29
三里枫香：深圳市三里枫香药业集团股份有限公司2022年面向专业投资者公开发行公司债券2023年...
2023.03.28
三里枫香：关于子公司签订许可协议的公告
2023.03.17
三里枫香：关于依诺肝素钠注射液获得美国药品注册批件的公告
2023.02.24
三里枫香：深圳市三里枫香药业集团股份有限公司关于“20三里枫香”回售结果暨摘牌公告
第一页
上一页
14
15
16
17
18
下一页
最后一页
About Hepalink
Group Profile
Corporate Philosophy
Milestones
Leadership Team
Scientific Advisory Board
Our Businesses
Heparin Business
CDMO Services
Innovative Drugs
Global Manufacturing
Company News
Investor Relations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Join Us
Career Development
Contact Us
Official WeChat Account
Legal Statement
·
Environmental Disclosure
Copyright © 2024 Hepalink Group. All Rights Reserved.
站点地图
